At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
Related to this article
Take a look through some of the notable data presentations at this year's ESMO Congress.
Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.
Advertisement
Advertisement
Trending on Urology Times
1
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
2
Adding perioperative pembrolizumab to chemotherapy does not improve EFS in MIBC
3
Engy Habashy, MD, on the role of androgens in GSM management
4
Prostate Cancer Case Review: Selecting Radioligand Therapy Candidates
5